contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  availableLanguages
  pageUrl
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


share-subscriptions-based-on-the-resolution-by-nanoform-finland-plcs-annual-general-meeting-2024-on-remuneration-of-the-board-of-directors

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

availableLanguages

pageUrl

imgUrl

description

Nanoform Finland is a medical technology company. The company specializes in the research and development of technical products used to create nanoparticles in pharmaceuticals. The technology is used as a complement in the production process and is used for the treatment of diseases such as ALS and Alzheimer's. The customers consist of companies in the global pharmaceutical industry. Nanoform Finland mainly operates in the Nordic market and is headquartered in Helsinki.

Nanoform Finland

Company releaseNanoform Finland PlcJune 14, 202417:00 Finnish time / 16.00 Swedish timeShare subscriptions based on the resolution by Nanoform Finland Plc's Annual General Meeting 2024 on remuneration...

Company releaseNanoform Finland PlcJune 14, 202417:00 Finnish time / 16.00 Swedish timeShare subscriptions based on the resolution by Nanoform Finland Plc's Annual General Meeting 2024 on remuneration of the Board of DirectorsHelsinki, Finland - A total of 85,072 Nanoform Finland Plc's (the "Company" or "Nanoform") new shares has been subscribed for by the members of the Board of Directors of the Company. &nbsp;The shares are issued as part of remuneration of the members of the Board of Directors in accordance with the resolution by the Company's Annual General Meeting April 16, 2024 (the "AGM"). As noted in the AGM, the share price 2.01 euros corresponds to volume-weighted average share price over ten (10) trading days following the publication of the interim report of the Company for 1 January 2024 - 31 March 2024 (the "Q1 Report"). The Q1 Report was published on May 30, 2024.The entire subscription price of EUR 171,000 for the share subscriptions will be entered in the Company's reserve for invested unrestricted equity. The shares subscribed for are expected to be registered in the Trade Register on or about June 25, 2024, as of which date the new shares will establish shareholder rights and the total amount of shares in the Company will be 85,530,236. The shares will be traded on the NASDAQ Helsinki Plc's First North Growth Market Finland marketplace together with the old shares on or about June 26, 2024.For further information, please contact:Peter Hänninen, General Counselpeter.hanninen@nanoform.com+358 50 353 0408For investor relations queries, please contact:Henri von Haartman, Director of Investor Relationshvh@nanoform.com+46 7686 650 11About NanoformNanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP nano-API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services, from pre-clinical to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 744 1900. For more information, please visit www.nanoform.com.

Share subscriptions based on the resolution by Nanoform Finland Plc's Annual General Meeting 2024 on remuneration of the Board of Directors

Tilmeld dig vores nyhedsbrev - ingen konto nødvendig!